The inhibition of EZH2 in Ewing sarcoma cells resulted in a loss of their ability to grow independently in vitro and their tumorigenic potential in vivo, highlighting EZH2 as a potential therapeutic target. Here, EZH2 is linked to Ewing sarcoma.